Maddi Hebebrand, MC, Associate Editor

Swanson and Lockshin explored how PDE4 inhibitors improve quality of life for AD patients through targeted treatments that address both inflammation and chronic symptoms.

Researchers emphasized the need for future studies to refine protocols and address economic barriers to combination therapy.

Researchers found two-thirds of patients reported no impact of psoriasis on their quality of life after 52 weeks of treatment with deucravacitinib.

The review found AD can disrupt family life, as caregiving responsibilities can lead to stress, guilt, and reduced opportunities for shared activities.

Despite the risks of sun exposure, a study found only a fraction of coaches receive adequate UV-related guidance from their associations or clubs.

Researchers found patients reporting greater disease burden and lower HRQoL are more likely to switch to biologic therapies, regardless of clinician-rated disease severity.

Researchers stated that therapy represents a “valuable nonpharmacological intervention that offers an innovative therapeutic alternative” for acne treatment.

Researchers found integrating dermatologists into primary care reduces costs and improves diagnostic precision for skin conditions.

Researchers found patients treated with risankizumab had higher rates of skin clearance and greater improvement than those treated with deucravacitinib.

LOV has unique clinical traits, epidemiology, and treatment responses compared to early-onset vitiligo, underscoring the need for a tailored management approach.

Hawkes highlighted how second-generation TYK2 inhibitors improve upon earlier oral therapies with greater efficacy and selectivity.

Hawkes highlighted the intersection of oncology and dermatology, focusing on immune checkpoint inhibitors and their cutaneous adverse events.

Unlike previous therapies, bimekizumab has shown continued efficacy at 48 and 96 weeks, offering long-term benefits to HS patients.

The pivotal BE HEARD trials demonstrated bimekizumab’s efficacy, showing meaningful improvements over placebo in HS patients.

According to the company, comparative tests revealed PN-881 surpasses or matches the efficacy of current injectable IL-17 therapies.

Researchers found the TYK2 inhibitor deucravacitinib offers superior efficacy to apremilast and comparable outcomes to biologics.

The study underscores the need for careful dietary advice to balance effective AD management and minimize food allergy risks.

Research suggested acne is primarily inflammatory, occurring even in unaffected skin, redefining its pathophysiology.

The drug is the first FDA-approved treatment for moderate to severe HS that selectively inhibits both IL-17A and IL-17F.

The company’s phase 3 trials show JNJ-2113 significantly improves skin clearance and tolerability for patients with moderate to severe psoriasis.

Patients treated with dupilumab saw substantial healing, with over 70% achieving >50% lesion improvement in 24 weeks.

November's cover feature highlights the revolutionary role of artificial intelligence in the development of zasocitinib for the treatment of psoriasis.

A recent analysis found primary closure in HS surgery has higher recurrence rates, while secondary intention healing avoids complications but prolongs recovery.

Delgocitinib is indicated for adults with CHE who either do not respond to or cannot use topical corticosteroids.

The study calls for improved diversity in clinical training materials to help future clinicians better recognize conditions on darker skin.

Murase discussed safe dermatologic treatments during lactation, especially for chronic conditions needing biologics.

Murase identifies 4 main pregnancy dermatoses—atopic eruption, polymorphic eruption, extrahepatic cholestasis, and pemphigoid gestationis—as "baby bumps."

Murase noted small molecule treatments, like JAK inhibitors, remain unsafe for pregnant women.

The study demonstrated significant reductions in inflammatory and non-inflammatory lesions for Hispanic patients using CAB gel.